Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07145918 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 268
- Enrollment target
- 7
- Study locations
NCT07145918 is a Phase 2 study of Schizophrenia that is actively recruiting participants, run by AbbVie. The registered enrollment target is 268 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (23% higher). The trial reports 7 study locations across 5 states.
The verdict
NCT07145918, a Phase 2 study of Schizophrenia, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 268 participants
- Enrollment target
- 7
- Study locations
Study Summary
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 268 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Emraclidine
Study Locations (7)
California
- Collaborative Neuroscience Research - Garden Grove /ID# 273005 - Garden Grove
- California Clinical Trials Medical Group - Parexel /ID# 275751 - Glendale
Texas
- Community Clinical Research - Austin - Cross Park Drive /ID# 272977 - Austin
- Pillar Clinical Research - Richardson /ID# 275715 - Richardson
Arkansas
- Woodland International Research Group /ID# 275747 - Little Rock
Maryland
- Cbh Health - Gaithersburg /ID# 272932 - Gaithersburg
New Jersey
- Cenexel Hassman Research Institute (Hri) /ID# 276128 - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07145918
The ClinicalTrials.gov registry entry for NCT07145918 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (23% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07145918 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Arkansas.
Frequently Asked Questions
What is clinical trial NCT07145918 about?
NCT07145918 is a clinical study titled "A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia". Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult parti...
What is the current status of trial NCT07145918?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2025-08-04. Estimated completion is 2028-02.
What conditions does trial NCT07145918 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07145918?
The interventions under investigation include: Placebo (DRUG), Emraclidine (DRUG).
Who is sponsoring clinical trial NCT07145918?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07145918 being conducted?
This trial has 7 study locations across Arkansas, California, Maryland, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
-
A Study of ANAVEX3-71 in Adults With Schizophrenia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.